Frontiers

Upfront

Beating Cancer The ultimate solution to beating cancer would be to avoid it altogether. We can do that to a large degree through lifestyle changes, by minimizing environmental risks and through research that enables us to ...[Read more]
Published: Jul-19-12 | 1  Comment | 0  Link to this post

Frontline-The Researcher's Voice

Radiation Therapy for Breast Cancer Progress in clinical practice and personalizing treatment requires clinical trials By JULIA WHITE, MD, director of Breast Radiation Oncology and vice chair for Clinical Research, Department of Radiation Onc ...[Read more]
Published: Jul-19-12 | 0  Comment | 0  Link to this post

Breakthrough

CELLULAR COLLABORATION Study Shows How Normal Cells Fuel Tumor Growth MICHAEL OSTROWSKI, PhD, (right), OSUCCC – James Co-leader of the Molecular Biology and Cancer Genetics Program GUSTAVO LEONE, PhD, OSUCCC ...[Read more]
Published: Jul-19-12 | 0  Comment | 0  Link to this post

Of Note

AWARDS AND RECOGNITIONS  ​ CLARA D. BLOOMFIELD, MD, Distinguished University Professor, cancer scholar and senior adviser to the OSUCCC – James, was awarded the 2012 Richard L. Schilsky Cancer and Leukemia Group B Achievement Award ...[Read more]
Published: Jul-19-12 | 0  Comment | 0  Link to this post

Saving Life and Limb

SAVING LIFE AND LIMB Joel Mayerson, MD, leads a sarcoma team that tackles cases other hospitals turn away. BY KENDALL POWELL When orthopaedic oncologist Joel Mayerson, MD, and a team of surgeons resected the softballsize ...[Read more]
Published: Jul-19-12 | 1  Comment | 0  Link to this post

The Power of Prevention

THE POWER OF PREVENTION The adage that "an ounce of prevention equals a pound of cure" carries substantial weight in the realm of cancer control. BY BOB HECKER ARTWORK BY RICHARD LILLASH "You are th ...[Read more]
Published: Jul-19-12 | 0  Comment | 0  Link to this post

Drug Design in silico

ROBERT BAIOCCHI, MD, PhD, assistant professor of Medicine and a member of the OSUCCC – James Viral Oncology ProgramCHENGLONG LI, PhD, associate professor of Medicinal Chemistry and Biophysics, and a member of the OSUCCC – James ...[Read more]
Published: Jul-19-12 | 0  Comment | 0  Link to this post

Bench to Bedside

An open-label, phase 1b/2, safety and efficacy study of the Bruton's tyrosine kinase (Btk) inhibitor, PCI-32765, and ofatumumab in subjects with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and prolymphocytic leu ...[Read more]
Published: Jul-19-12 | 0  Comment | 0  Link to this post

 Next >>